Zusammenfassung
Wegen seiner nach wie vor schlechten Prognose bleibt das duktale Pankreaskarzinom weiterhin eine Herausforderung an multimodale Therapiekonzepte. Hierbei hat die Strahlentherapie, heute für gewöhnlich als simultane Radiochemotherapie (RCT) appliziert, ihren Platz zu definieren und zu behaupten. Dies verlangt nach interdisziplinär sorgfältig geplanten Therapiestudien, welche die Möglichkeiten der einzelnen Therapiebausteine sinnvoll einsetzten. Bisher ist leider die Datenlage bei der adjuvanten bzw. neoadjuvanten Therapie unbefriedigend. Nach einer R0-Resektion werden die Patienten in Europa überwiegend der adjuvanten Chemotherapie zugeführt. In Nordamerika ist aufgrund der GITSG- Daten die Radiochemotherapie Standard. Diese ist eine sinnvolle Behandlungsoption insbesondere bei Patienten mit Pankreaskopfkarzinom, pN1-Status und einem maximalen Tumordurchmesser von > als 3 cm. Zusätzlich sollte sie nach einer R1-Resektion empfohlen werden. Aufgrund des Fehlens prospektiv randomisierter Studien kann zur neoadjuvanten Radiochemotherapie derzeit noch nichts Abschließendes gesagt werden. Es ist jedoch zu erwarten, dass die neoadjuvante RCT zu einer Verbesserung des Gesamtüberlebens führt durch Steigerung der R0-Resektabilität, eine erhöhte ypN0-Rate und eine verbesserte lokale Tumorkontrolle. Bei lokal fortgeschrittenen Karzinomen ohne Fernmetastasen sind wohl die Überlebensraten nach RCT tendenziell besser als nach alleiniger Chemotherapie. Der wichtigste Punkt dabei ist, dass die RCT in 15 - 20 % der Fälle sekundär eine kurativ intendierte Tumorresektion ermöglicht. Mehr als bei anderen Tumoren bestimmt das Bestrahlungsvolumen die Verträglichkeit und damit Durchführbarkeit einer simultanen RCT. Das Zielvolumen umfasst den Primärtumor und die Lymphabflussgebiete peripankreatisch, trunkal, hepatoduodenal, mesenterial und interaortocaval bis zum Abgang der A. mesenterica inferior. Eine Gesamtdosis von 50 - 55 Gy wird in Einzelfraktionen von 1,8 - 2,0 Gy fraktioniert. Ungewöhnliche Toxizität tritt immer dann auf, wenn diese Regeln nicht ausreichend beachtet werden.
Summary
Ductal pancreatic carcinoma remains a challenge for multimodal therapeutic concepts because of its still dismal prognosis. Within this context the role of radiotherapy - usually administered as concurrent chemoradiation - has to be defined and to stand the test of time. This requires carefully planned trials that use the inherent power of each of the respective therapeutic modalities in a reasonable way. To date, the data for adjuvant and neoadjuvant therapy are unfortunately insufficient. After clear resection (R0) patients in Europe are preferentially treated with adjuvant chemotherapy. In northern America chemoradiation (CRT) is standard based upon the GITSG data. CRT is a reasonable option for patients with cancer of the pancreatic head, with positive nodes and with a maximal tumor diameter > 3 cm. Additive CRT should be recommended after non-curative resection (R1). The value of neoadjuvant CRT has not yet been proven on the highest level of evidence since prospectively randomized trials have not been completed yet. However, we expect longer survival after neoadjuvant CRT through higher rates of R0-resections, lower rates of nodal spread (ypN1) and higher local tumor control. Survival of patients with locally advanced pancreatic cancer (LAPC) without distant metastasis has a tendency to be longer after CRT compared to chemotherapy alone. It should always be kept in mind that CRT allows secondary tumor resection with curative intent. More than in other tumors, volume of radiation directly corresponds to tolerability and feasibility of concurrent CRT. The clinical target volume contains the primary tumor and the regional lymphatic areas (peripancreatic, celiac trunk, hepatoduodenal, mesenteric, and interaortocaval between the celiac trunk and the inferior mesenteric artery). A total dose of 50 - 55 Gy is given in fractions of 1.8 to 2.0 Gy. Unexpected toxicity has repeatedly been described when these technical aspects have been neglected.
Schlüsselwörter
Pankreaskarzinom - Radiochemotherapie
Key words
pancreatic cancer - chemoradiation
Literatur
-
1
Abrams R A, Lillemoe K D, Piantadosi S.
Continuing controversy over adjuvant therapy of pancreatic cancer.
Lancet.
2001;
358
1565-1566
-
2
Berlin J D, Catalano P, Thomas J P, Kugler J W, Haller D G, Benson A B.
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
J Clin Oncol.
2002;
20
3270-3275
-
3
Brunner T B, Grabenbauer G G, Kastl S, Herrmann O, Baum U, Fietkau R, Klein P, Bautz W, Schneider T, Hohenberger W, Sauer R.
Preoperative chemoradiation in locally advanced pancreatic carcinoma: A phase II study.
Onkologie.
2000;
23
436-442
-
4
Brunner T B, Grabenbauer G G, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R.
Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer(1).
Int J Radiat Oncol BiolPhys.
2003;
55
144-153
-
5
Brunner T B, Merkel S, Grabenbauer G G, Meyer T, Baum U, Papadopoulos T, Sauer R, Hohenberger W.
Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based upon histopathologic analysis.
Int J Radiat Oncol Biol Phys.
2005;
62
1021-1029
-
6
Brunner T B, Tinkl D, Grabenbauer G G, Meyer T, Brueckl W M, Sauer R.
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Strahlenther Onkol.
2006;
182
210-215
-
7
Chauffert B, Mornex F, Bonnetain F, Triboulet J P, Bouche O, Rougier P, Bosset J F, Aparicio T, Masskouri F, Bedenne L.
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.
J Clin Oncol.
2006;
24(18S)abstract
4008
-
8
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M.
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale.
Cancer.
2002;
94
902-910
-
9
Crane C H, Abbruzzese J L, Evans D B, Wolff R A, Ballo M T, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters P W, Lee J E, Lenzi R, Vauthey J N, Wong A B, Phan T, Nguyen Q, Janjan N A.
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?.
Int J Radiat Oncol Biol Phys.
2002;
52
1293-1302
-
10
Crane C H, Wolff R A, Abbruzzese J L, Evans D B, Milas L, Mason K, Charnsangavej C, Pisters P W, Lee J E, Lenzi R, Lahoti S, Vauthey J N, Janjan N A.
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.
Semin Oncol.
2001;
28
25-33
-
11
Dunst J, Diestelhorst A, Kuhn R, Muller A C, Scholz H J, Fornara P.
Organ-sparing treatment in muscle-invasive bladder cancer.
Strahlenther Onkol.
2005;
181
632-637
-
12
Eich H T, Muller R P, Micke O, Kocher M, Berthold F, Hero B.
Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?.
Strahlenther Onkol.
2005;
181
378-384
-
13
Evans D B, Rich T A, Byrd D R, Cleary K R, Connelly J H, Levin B, Charnsangavej C, Fenoglio C J, Ames F C.
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Arch Surg.
1992;
127
1335-1339
-
14
Garofalo M, Flannery T, Regine W.
The case for adjuvant chemoradiation for pancreatic cancer.
Best Pract Res Clin Gastroenterol.
2006;
20
403-416
-
15
GITSG .
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.
J Natl Cancer Inst.
1988;
80
751-755
-
16
Huguet F, André T, Hammel P, Artru P, Balosso J,
Selle
F,
Deniaud-Alexandre
E,
Ruszniewski P, Touboul E, de Gramont A, Louvet C.
Impact of chemoradiotherapy after disease control with chemotherapy in locally-advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
J Clin Oncol.
2007;
25
326-331
-
17
Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H.
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
Cancer.
1997;
79
1516-1520
-
18
Johnson C D, Puntis M, Davidson N, Todd S, Bryce R.
Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma.
Br J Surg.
2001;
88
662-668
-
19
Kachnic L A, Shaw J E, Manning M A, Lauve A D, Neifeld J P.
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Int J Cancer.
2001;
96
132-139
-
20
Kalser M H, Ellenberg S S.
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection [published erratum appears in Arch Surg 1986 Sep;121(9):1045].
Arch Surg.
1985;
120
899-903
-
21
Khanna A, Walker G R, Livingstone A S, Arheart K L, Rocha-Lima C, Koniaris L G.
Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question.
J Gastrointest Surg.
2006;
10
689-697
-
22
Klaassen D J, MacIntyre J M, Catton G E, Engstrom P F, Moertel C G.
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study.
J Clin Oncol.
1985;
3
373-378
-
23
Klinkenbijl J H, Jeekel J, Sahmoud T, van Pel R, Couvreur M L, Veenhof C H, Arnaud J P, Gonzalez D G, de Wit L T, Hennipman A, Wils J.
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Ann Surg.
1999;
230
776-782
-
24
Louvet C, Labianca R, Hammel P, Lledo G, Zampino M G, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A.
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
J Clin Oncol.
2005;
23
3509-3516
-
25
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O’Brien M, Tebbutt N, Harrington A, Hill M.
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
J Clin Oncol.
2002;
20
3130-3136
-
26
Matsuda T, Taniguchi F, Minato H, Nomura H, Tsuda T, Aikawa I.
Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case.
Surgery today.
2006;
36
754-757
-
27
McGinn C J, Zalupski M M, Shureiqi I, Robertson J M, Eckhauser F E, Smith D C, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence T S.
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
J Clin Oncol.
2001;
19
4202-4208
-
28
Neoptolemos J P, Dunn J A, Stocken D D, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr D J, Friess H, Buchler M W.
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Lancet.
2001;
358
1576-1585
-
29
Neoptolemos J P, Stocken D D, Friess H, Bassi C, Dunn J A, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr D J, Buchler M W.
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
N Engl J Med.
2004;
350
1200-1210
-
30
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W O, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H.
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
J Am Med Assoc.
2007;
297
267-277
-
31
Pisters P W, Abbruzzese J L, Janjan N A, Cleary K R, Charnsangavej C, Goswitz M S, Rich T A, Raijman I, Wolff R A, Lenzi R, Lee J E, Evans D B.
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
J Clin Oncol.
1998;
16
3843-3850
-
32
Raut C P, Evans D B, Crane C H, Pisters P W, Wolff R A.
Neoadjuvant therapy for resectable pancreatic cancer.
Surg Oncol Clin N Am.
2004;
13
639-661
-
33
Regine W, Winter K, Abrams R, Safran H, Hoffman J, Konski A, Benson A, MacDonald J, Willett C, Rich T.
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma.
J Clin Oncol.
2006;
24(18S)abstract
4007
-
34
Rocha Lima C M, Green M R, Rotche R, Miller W H, Jeffrey G M, Cisar L A, Morganti A, Orlando N, Gruia G, Miller L L.
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
J Clin Oncol.
2004;
22
3776-3783
-
35
Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli P M, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D.
EUROCARE-3: survival of cancer patients diagnosed 1990 - 94 - results and commentary.
Ann Oncol.
2003;
(Suppl 5)
14)
v61-118
-
36
Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T.
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.
Int J Radiat Oncol Biol Phys.
2002;
53
146-150
-
37
Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L.
Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Cancer.
2000;
89
314-327
-
38
Stocken D D, Buchler M W, Dervenis C, Bassi C, Jeekel H, Klinkenbijl J H, Bakkevold K E, Takada T, Amano H, Neoptolemos J P.
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.
Br J Cancer.
2005;
92
1372-1381
-
39
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne W L, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D.
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
J Clin Oncol.
2004;
22
1430-1438
-
40
Wayne J D, Wolff R A, Pisters P W, Evans D B.
Multimodality management of localized pancreatic cancer.
Cancer J.
2001;
(Suppl 1)
7
S35-46
-
41
White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, Pappas T, Hurwitz H, Tyler D.
Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
Ann Surg Oncol.
1999;
6
38-45
-
42
White R R, Hurwitz H I, Morse M A, Lee C, Anscher M S, Paulson E K, Gottfried M R, Baillie J, Branch M S, Jowell P S, McGrath K M, Clary B M, Pappas T N, Tyler D S.
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.
Ann Surg Oncol.
2001;
8
758-765
-
43
White R R, Xie H B, Gottfried M R, Czito B G, Hurwitz H I, Morse M A, Blobe G C, Paulson E K, Baillie J, Branch M S, Jowell P S, Clary B M, Pappas T N, Tyler D S.
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.
Ann Surg Oncol.
2005;
12
214-221
-
44
Wilkowski R, Thoma M, Duhmke E, Rau H G, Heinemann V.
Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.
Int J Radiat Oncol Biol Phys.
2004;
58
768-772
-
45
Wilkowski R, Thoma M, Heinemann V, Rau H G, Wagner A, Stoffregen C, Duhmke E.
Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective.
Strahlenther Onkol.
2003;
179
78-86
-
46
Wolff R A, Evans D B, Crane C H, Cleary K R, Lenzi R, Abbruzzese J L, Charnsangavej C, Tamm E, Janjan N J, Delclos M, Vauthey J V, Lee J E, Pisters P W.
Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma (Abstract 516).
J Clin Oncol.
2002;
20
516
-
47
Yeo C J, Abrams R A, Grochow L B, Sohn T A, Ord S E, Hruban R H, Zahurak M L, Dooley W C, Coleman J, Sauter P K, Pitt H A, Lillemoe K D, Cameron J L.
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single- institution experience.
Ann Surg.
1997;
225
621-633
-
48
Brunner T B, Grabenbauer G G, Meyer T, Golcher H, Sauer R, Hohenberger W.
Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).
BMC Cancer.
2007;
7
41
Priv.-Doz. Dr. Thomas Brunner
University of Oxford, Radiation Oncology & Biology, Churchill Hospital
Headington, Oxford OX3 7LJ
United Kingdom
Telefon: 0044/1865/857126
Fax: 0044/1865/857127
eMail: thomas.brunner@rob.ox.ac.uk
